KALA BIO posts Q4 net loss of $8.2M; Phase 2b topline data delayed to 3Q25

KALA BIO, Inc.

2025-Q1 EPS reported -$1.41 vs consensus -$103.53 ▲ beat (+98.6%)

Randomized 87 patients in Phase 2b CHASE trial for KPI-012; extending enrollment due to 13 unverified patients; topline data now expected in 3Q25.
Raised $10.75M in December private placement with SR One, Cormorant, Woodline.
Cash and equivalents $51.2M at year-end; expected to fund operations into 1Q26.
Q4 operating loss $9.5M; net loss $8.2M ($1.74/share).
Full year 2024 net loss $38.5M ($10.15/share); no revenue.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001558370-25-004080
form_type: 8-K
ticker: KALA
cik: 0001479419
company_name: KALA BIO, Inc.
filed_at: 2025-03-31T23:59:59+00:00
discovered_at: 2026-05-14T18:03:03.743602+00:00
generated_at: 2026-05-24T01:42:02.721826+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: negative
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001558370-25-004080
json_url: https://secwatch.observer/filing/0001558370-25-004080.json
markdown_url: https://secwatch.observer/filing/0001558370-25-004080.md
text_url: https://secwatch.observer/filing/0001558370-25-004080.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1479419/000155837025004080/0001558370-25-004080-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1479419/000155837025004080/kala-20250331x8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001558370-25-004080

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.